The aim of this article is to provide an overview of mega-merger activity in western pharmaceutical markets and the reasons for it, and also to explain why we believe mega-merger activity will likely continue in the future. We will also consider a fictitious mega-merged Japanese company and where it would fit in the global pharmaceutical market.
